Featured Commentary


Highlights/ StockHighlights

Dow 30 Earnings: Pfizer Third Quarter 2017

10/31/2017 Drugmaker and Dow-30 component Pfizer reported better-than-expected September-quarter earnings, but the stock pulled back slightly following the release.
read more

Daily Updates/ Markets

Stock Market Today: October 30, 2017

10/30/2017 The stock market kicked off the new trading week with an uninspiring performance. At the close of the day, the Dow Jones Industrial Average was down roughly 85 points; the broader S&P 500 Index was off eight points; and the NASDAQ was lower by two points. Meanwhile, market breadth showed a negative bias to the session, as decliners easily outpaced advancers on the NYSE. Most of the major equity sectors lost ground, with considerable declines in the industrial, healthcare, and consumer names. In contrast, energy stocks forged ahead. Technology issues also made progress.
read more

Daily Updates/ Market Daily Updates

Stock Market Today: October 11, 2017

10/11/2017 The stock market got off to a tentative start this morning, but managed to shape up nicely as the session progressed. At the close of trading, the Dow Jones Industrial Average was up 42 points; the broader S&P 500 Index was ahead nearly five points; and the NASDAQ was higher by 16 points.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer Second Quarter 2017

08/01/2017 New York-based drugmaker and Dow-30 component Pfizer (PFE) has reported second-quarter earnings of $0.51 a share, versus $0.33 in the comparable period of 2016. The year-over-year improvement was driven primarily by a sharp decline in production costs (-16%), which more than offset a 2% pullback in sales.
read more

Daily Updates/ Market Daily Updates

Stock Market Today: May 2, 2017

05/02/2017 The stock market put in another mixed session today, as traders digested the latest batch of corporate earnings reports and speculated about the Federal Reserve’s next move. At the close of trading, the Dow Jones Industrial Average was ahead 34 points, while the broader S&P 500 Index was up slightly, and the NASDAQ was ahead modestly, as well.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer First Quarter 2017

05/02/2017 New York-based drugmaker and Dow-30 component Pfizer (PFE) has reported first-quarter earnings of $0.51 a share, versus $0.49 in the comparable period of 2016. The bottom-line improvement was fueled primarily by reduced production costs (-13%) and, to a lesser extent, lower SG&A (-2%) and R&D (-1%) outlays, which helped mitigate a 2% year-over-year dip in sales. Meantime, adjusted earnings, which excluded one-time gains, charges, and other nonrecurring items, and are more closely followed by Wall Street, came in at $0.69 a share, versus $0.67 in 2016.
read more

Daily Updates/ Market Daily Updates

Stock Market Today: May 1, 2017

05/01/2017 Equities put in a mixed, but selectively constructive, session today, as we embarked on a new week. At the end of trading, the Dow Jones Industrial Average was down 27 points; the broader S&P 500 Index was up four points; and the NASDAQ was higher by 44 points. Many stocks managed to forge ahead, as winners slightly outpaced losers on the NYSE. From a sector perspective, the technology and financial issues displayed leadership, while the utility names retreated.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer Fourth Quarter 2016

01/31/2017 New York-based drugmaker and Dow-30 component Pfizer (PFE) has reported fourth-quarter earnings of $0.13 a share, versus a loss of $0.03 a share in the comparable period of 2015. Meanwhile, adjusted earnings, which exclude one-time gains, charges, and other nonrecurring items, and are more closely followed by Wall Street, came in at $0.47 a share, versus $0.53 in 2015.
read more

Commentaries/ StockCommentary

Dogs Of The Dow: 2016 in Review

01/30/2017 The Dogs of the Dow investment strategy produced market-beating returns for 2016. A Dogs of the Dow portfolio (consisting of equally weighted positions in the top 10 highest yielding Dow issues at the start of the year) would have risen 16% on the year. The advance was led by Caterpillar (CAT), which was up more than 35% in price, while Chevron (CVX) rose just over 30%, good enough for second-best among the Dogs. Meanwhile, the leading equity benchmarks also participated in the stock market’s 2016 advance, though the gains on the NASDAQ and the S&P 500 couldn’t measure up to those posted by the Dogs.
read more

PAGE
OF 11